Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2601

A Cytometric Assay for Monitoring Adalimumab Immunogenicity and Drug Concentrations Can Distinguish Anti-Adalimumab Antibodies from Interference

9:00AM-11:00AM: Abstract Number: 2583

Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients

9:00AM-11:00AM: Abstract Number: 2658

Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2608

Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab

9:00AM-11:00AM: Abstract Number: 2624

Anti-Citrullinated Protein Antibodies Titers Are Independently Modulated By Disease Activity and Synthetic or Biologic Dmards in a Seropositive Early Arthritis Population

9:00AM-11:00AM: Abstract Number: 2602

Anti-TNF Therapy Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas

9:00AM-11:00AM: Abstract Number: 2591

Association Between Flare and Radiographic Progression in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2654

Association Between Rheumatoid Factor Positivity and Effects of Treatment with a First Biologic Agent in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2640

Can GP88 (Progranulin) be Used to Predict the Efficacy of Infliximab?

9:00AM-11:00AM: Abstract Number: 2611

Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2637

Clinical Trials Aiming to Prevent the Development of Rheumatoid Arthritis Cannot Detect Prevention without Adequate Risk Stratification; A Trial Performed in UA-Patients As Example

9:00AM-11:00AM: Abstract Number: 2596

Comparable Safety and Immunogenicity and Sustained Efficacy after Transition to SB2 (An Infliximab Biosimilar) Vs Ongoing Reference Infliximab (Remicade®) in Patients with Rheumatoid Arthritis: Results of Phase III Transition Study

9:00AM-11:00AM: Abstract Number: 2586

Comparison of Intra-Articular Methylprednisolone Acetate with Triamcinolone Acetonide in Acutely Swollen Knee Joint of Patients with Chronic Inflammatory Arthritis – a Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2589

Comparison of Two Enzyme-Linked Immunosorbent Assays Used for Drug Concentration Monitoring in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

9:00AM-11:00AM: Abstract Number: 2598

Conversion Rate of Tuberculosis Screening Tests in Patients with Rheumatic Diseases While Receiving Anti-Tumor Necrosis Factor Alpha (anti-TNFα) Agents

9:00AM-11:00AM: Abstract Number: 2647

Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)

9:00AM-11:00AM: Abstract Number: 2630

EBV Load Quantification in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis Treated By Abatacept and Tocilizumab

9:00AM-11:00AM: Abstract Number: 2617

Economic Burden of Non-Responders to Biologic DMARD Treatments in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2633

Effect of Different Biologic Agents on Lipid Profile in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2606

Effect of Glucocorticoids on Clinical and Radiographic Efficacy Outcomes in Methotrexate-Naive Patients with RA Receiving Tofacitinib or Methotrexate Monotherapy: Analysis of Data from a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 2615

Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors

9:00AM-11:00AM: Abstract Number: 2632

Effects of Baseline Patient Characteristics on Baricitinib Efficacy in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2579

Etanercept Treatment Does Not Adversely Affect Traditional Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2607

Favorable Changes in Lipid Profile with Additive DMARD Therapy in Rheumatoid Arthritis Patients Failing Methotrexate Monotherapy

9:00AM-11:00AM: Abstract Number: 2610

Immunogenicity Assessment of Biologics in Clinical Studies in Chronic Inflammatory Disease: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2638

In Vitro Expansion of Treg By Adaimumab Predicts Clinical Response to Therapy in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2621

Incremental Benefit of Radiographic Inhibition on Long-Term Outcomes in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2623

Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase 1, Proof-of-Concept Clinical Trial

9:00AM-11:00AM: Abstract Number: 2634

Lack of Autoantibodies to Peptidyl Arginine Deiminase 4 Predict Increased Efficacy of Mavrilimumab in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2582

N-Acetylcysteine Regulates Osteoclastogenesis and Th17 Cell Differentiation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2636

No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2649

Patient Preferences Regarding Rheumatoid Arthritis Therapies in Lebanon: Results from a National, Multicenter, Cross-Sectional Survey

9:00AM-11:00AM: Abstract Number: 2644

Patient Survey Regarding Generic and Bio-Similar Drugs

9:00AM-11:00AM: Abstract Number: 2594

Physician/Site Staff Assessments Contribute to High Placebo Response in Rheumatoid Arthritis Clinical Trials

9:00AM-11:00AM: Abstract Number: 2639

Predicting Flare and Sustained Clinical Remission after Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score

9:00AM-11:00AM: Abstract Number: 2650

Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 2648

Predictive Role of Biomarkers for the Response to Biologic Therapy in Rheumatoid Arthritis. Old, New and How Future Looks like?

9:00AM-11:00AM: Abstract Number: 2651

Predictors of Inadequate Response and Rapid Radiographic Progression in Patients with Early Rheumatoid Arthritis Receiving Methotrexate: a Post Hoc Analysis of 2 Randomized, Controlled Trials of Adalimumab

9:00AM-11:00AM: Abstract Number: 2655

Prevalence and Risk Factors of Reactivation of Resolved Hepatitis B Virus in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 2584

Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 2603

Real World Practice Based Clinical Study of Delayed-Release Prednisone Produces Comparable Results to a Controlled Clinical Trial: Morning Stiffness and Disease Measures in Moderate-Severe RA Patients Switched from Immediate-Release to Delayed Release-Prednisone

9:00AM-11:00AM: Abstract Number: 2595

Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry

9:00AM-11:00AM: Abstract Number: 2653

Results of a Comprehensive Review of Pulmonary Function and Safety Data in a Phase IIb Clinical Program Testing Anti-GM-CSF Receptor Antagonist Mavrilimumab for Treatment of RA

9:00AM-11:00AM: Abstract Number: 2656

Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country

9:00AM-11:00AM: Abstract Number: 2628

Retention of Use and Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: A Patient Record Assessment in a Compassionate Use Programme in South Africa, a Tuberculosis Endemic Country

9:00AM-11:00AM: Abstract Number: 2620

Retrospective Analysis for Determining the Signs and Symptoms of Infections before They Become Serious in Tocilizumab-Treated RA Patients Using a Postmarketing Adverse Events Reporting Database

9:00AM-11:00AM: Abstract Number: 2652

Rheumatoid Arthritis and Excess Mortality Associated with Treatments: a Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2643

Risk Factors of Pneumocystis Jiroveci Pneumonia (PJP) in Patients with RA and Sulfasalazine As a Possible Protective Agent

9:00AM-11:00AM: Abstract Number: 2618

Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate (REGISTRY –ROACTEMRA)

9:00AM-11:00AM: Abstract Number: 2646

Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2625

Safety of Multiple Retreatments with Rituximab in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2641

Safety of Synthetic and Biological Dmards: Slr Informing the Update of the EULAR Recommendations for the Management of RA

9:00AM-11:00AM: Abstract Number: 2622

Safety, Pharmacokinetics, and Biomarker Profile from Phase 1 Clinical Trials of Healthy Volunteers Treated with GDC-0853, a Highly Selective Reversible Oral Bruton’s Tyrosine Kinase (BTK) Inhibitor

9:00AM-11:00AM: Abstract Number: 2629

Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry

9:00AM-11:00AM: Abstract Number: 2612

Sero-Positivity for Rheumatoid Factor Is an Independent Predictor for Achievement of Good EULAR Response at 24 Weeks in ACPA Positive Rheumatoid Arthritis Patients Treated with Abatacept: Results from Japanese Multicenter Registry

9:00AM-11:00AM: Abstract Number: 2613

Seropositivity for RF or ACPA Predicts Long Term Drug Retention with Rituximab, but Not with Abatacept and Tocilizumab : Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2585

Serum MMP-3 and OPG As Predictors of Response to Traditional Dmards in a Treatment NaïVe Early Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2614

Similar Rates of Death, Serious Infections, Cancers, Major Cardiovascular Events in Patients Treated with Abatacept, Rituximab and Tocilizumab: Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2626

Soluble CD206 Plasma Levels Decreases with Treatment and Reflects Anti-Tnfa Discontinuation in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2619

Sustained Suppression of Peripheral Biomarkers By Mavrilimumab but Not Golimumab in Anti-Tumor Necrosis Factor-Inadequate Responders: An Exploratory Analysis in the Phase IIb Earth Explorer 2 Clinical Trial

9:00AM-11:00AM: Abstract Number: 2599

TCZ Improves the Pro-Atherothrombotic Profile of Rheumatoid Arthritis Patients Modulating Endothelial Dysfunction, Netosis and Inflammation

9:00AM-11:00AM: Abstract Number: 2627

The Effect of Fostamatinib with Methotrexate on Circulating Biomarkers of Synovium, Cartilage and Bone Metabolism: Potential Utility for Clinical Development Decision Making in Rheumatoid Arthriti

9:00AM-11:00AM: Abstract Number: 2593

The Effect of Tofacitinib on Bone Mineral Density in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2609

The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated up to 19 Months with Tofacitinib

9:00AM-11:00AM: Abstract Number: 2590

The Efficacy of Additional Immunoadsorption on the Modulation of Disease Activity in Patients with Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2592

The Impact of Biologic Therapy Introduction on Hip and Knee Replacement Among Rheumatoid Arthritis Patients: An Interrupted Time Series Analysis Using the Clinical Practice Research Datalink

9:00AM-11:00AM: Abstract Number: 2616

The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2588

The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort

9:00AM-11:00AM: Abstract Number: 2587

The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission

9:00AM-11:00AM: Abstract Number: 2605

Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry

9:00AM-11:00AM: Abstract Number: 2597

Time to Initiation of Biologic Agents Is Associated with Glucocorticoid Use: Results from the Corrona Registry

9:00AM-11:00AM: Abstract Number: 2580

Tofacitinib Do Not Get Worse Subclinical Atherosclerosis Despite up-Regulating Serum Cholesterol in Methotrexate-Resistant Active Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2600

Tofacitinib Is Associated with an Impaired Function of NK Cells and a Defective Immunosurveillance Against B-Cell Lymphomas

9:00AM-11:00AM: Abstract Number: 2645

Treatments for Early Rheumatoid Arthritis (RA): A Systematic Review of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 2631

Trends and Factors Associated with Use of Biologic Agents As Monotherapy Among US Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2581

Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2604

Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2635

Using Patient Reported Outcomes to Inform a Treat to Target Treatment Approach in RA

9:00AM-11:00AM: Abstract Number: 2657

Withdrawal of Nonsteroidal Anti-Inflammatory Drugs in Rheumatoid Arthritis Patients with Low Disease Activity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].